BA-BCS 2024 PROGRAM
TUESDAY, SEPTEMBER 3
Welcome and Opening Keynote Lecture
15:00-17:450 Registration
17:45-18:00 Welcome from organizers
18:00-19:00 Opening Conference
Chairs: Claudia Lanari, IBYME-CONICET, Buenos Aires, Argentina and Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.
Robert Clarke, University of Manchester, Manchester, UK
The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis
19:00-20:00 Welcome Reception at IFIBYNE
WEDNESDAY, SEPTEMBER 4
9:30-11:00 / Session 1: Luminal breast cancer
Chairs: Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina and María F. Rubio, IDIM-UBA-CONICET, Buenos Aires, Argentina
9:30-10:00 Todd Miller, Medical College of Wisconsin Cancer Center, Milwaukee, USA.
Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.
10:00-10:30 Joseph Jerry, University of Massachusetts, Amherst, USA.
A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.
10:30-10:45 Abstract selected for oral presentation: RUNX2 expression correlates with tumor progression in luminal breast cancer patients. Yamil D Mahmoud, IBYME-CONICET.
10:45-11:00 Discussion
11:00-11:30 Coffee Break & Poster Session 1
11:30-13:00 / Session 2: Luminal breast cancer 2
Chairs: Natalia Rubinstein, iB3, FCEyN, UBA, Buenos Aires, Argentina and Vanina Medina, BIOMED-CONICET, UCA, Buenos Aires, Argentina
11:30-12:00 Jennifer Richer, University of Colorado, Aurora, USA.
AR action in ER+ breast cancer – preclinical and clinical trial updates
12:00-12:30 Federico Waisberg, Instituto Fleming, Buenos Aires
New treatments and biomarkers in hormone resistant (HR+) breast cancer.
12:30-12:45 Abstract selected for oral presentation: Inhibition of Rac1 activity enhances Tastuzumab sensitivity in Her2-positive breast cancer cells through cell cycle deregulation, Virginia Judith Wolos, Instituto de Oncología Ángel Roffo.
12.45-13:00 Discussion
13:00-14:30 / Lunch and Poster Session 1
14:40-15:00 Sponsor presentation: LOBOV Científica
14:30-16:30 / Session 3: Detection and treatment of TNBC
Chairs: Roxana Schillaci, IBYME-CONICET, Buenos Aires, Argentina and Maria José Rico, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.
15:00-15:30 Roger Chammas, Center for Translational Research in Oncology, University of São Paulo, Brazil.
miRNAs as biomarkers for early onset Triple Negative Breast Cancers.
15:30-16:00 Paolo Ceppi, University of Southern Denmark, Odense, Denmark.
Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?
16:00-16:30 Pablo Mandó, CEMIC, Buenos Aires, Argentina.
New therapeutic options for TNBC.
16:30-16:45: Abstract selected for oral presentation: Enhancing Paclitaxel efficacy in triple negative breast cancer through DKC1 inhibition with R1D2-10, Roman Nicolas Vilarullo, Universidad Nacional de Quilmes.
16:45-17:00 Discussion
17:00-17:30 Coffee break and Posters
17:30-19.00 / Round Table 1 (Spanish)
Coordinadoras: Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina y María Roqué, IHEM-CONICET, Mendoza, Argentina.
Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.
Adriana De Siervi IBYME-CONICET y Oncoliq, Buenos Aires, Argentina.
Javier Stigliano, Hospital Nacional Prof. A Posadas, Haedo, Argentina.
Manglio Rizzo, Departamento Oncología, Hospital Universitario Austral, Pilar, Argentina.
Julieta Pandolfi, Anatomía Patológica. Lab. Secuenciación. Hospital Italiano de Buenos Aires, Argentina.
Diego Marzese (participante virtual) Division of Surgical Oncology, Duke University School of Medicine (DUSM), Durham, USA.
THURSDAY, SEPTEMBER 6
9:30-11:15 / Session 4: Cancer Stem Cells and Tumor Initiation
Chairs: Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Catalina Lodillinsky, Instituto Ángel Roffo, Buenos Aires, Argentina
9:30-10:00 Fariba Behbod, University of Kansas, Kansas City, USA.
Ductal carcinoma in situ: Transcriptional diversity and stemness.
10:00-10:30 Jochen Maurer, University Hospital RWTH, Aachen, Germany.
Cancer stem cells as disease models in research – opportunities and challenges.
10:30-11:00 William Muller, Rosalind and Morris Goodman Cancer Center, Montreal, Canada.
Oncogene-mediated regulation of tumor immune microenvironment in mouse models of human breast cancer
11:00-11:15 Discussion
11:15-11:45 Coffee Break and Poster Session 2
11:45-13:30 / Session 5: Breast Cancer Genomics and Transcriptomics
Chairs: Ignacio Schor, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Marianela Candolfi, INBIOMED, FMED, UBA, Buenos Aires, Argentina.
11:45-12:15 Martin Abba, UNLP, La Plata, Argentina
Old questions, new tools
12:15-12:45 Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York City, USA.
Breast cancer genomics and resistance to CDK4/6i or on MSK Breast Molecular Tumor Board.
12:45-13:00 Gonzalo Gomez Abuin, Hospital Alemán, Buenos Aires
Utility of next generation sequencing in breast cancer
13:00-13:15 Abstract selected for oral presentation: Exploring the effects of non-coding somatic mutations in BAF complex deregulation and the malignant characteristics of triple-negative breast cancer, Pedro J. Salaberry, IFIBYNE-UBA-CONICET.
13:15-13:30 Discussion
13:30-15:00 Lunch and Posters Session 2
15:00-17:00/ Session 6: immunotherapy and Fighting treatment resistance
Chairs: Georgina Coló, INIBIBB-UNS, Bahía Blanca, Argentina and Germán A. Gil, CIQUIBIC, UNC-CONICET), Córdoba, Argentina
15:00-15-30 Adrian Lee, University of Pittsburgh, Pittsburgh, USA.
Endocrine resistance in breast cancer metastasis.
15:30-16:00 Dejan Juric, Massachusetts General Hospital, Boston, USA.
Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors
16:00-16:30 María Vivanco, CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.
Breast Cancer Heterogeneity and resistance to hormone therapy
16:30-16:45 Abstract selected for oral presentation: Preclinical and clinical role of MUC4/TNF axis in metastatic triple-negative breast cancer, Florencia Mauro, IBYME-CONICET.
16:45-17:00 Discussion
17:00-17:30 Coffee Break and Posters Session 2
17:30-19:00 / Round Table 2 (Spanish)
Coordinadores: Mario Rossi Universidad Austral, Pilar, Argentina y Pablo Mandó, CEMIC, Buenos Aires, Argentina
Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.
Manglio Rizzo, Servicio de Oncología Hospital Austral, Pilar, Argentina.
Fernando Petracci, Instituto Fleming, Buenos Aires, Argentina.
Estrella Levy, Instituto Fleming, Buenos Aires, Argentina.
20:30-21:30 Tango Concert at Museo Nacional de Ciencias Naturales Bernardino Rivadavia (separate registration)
FRIDAY, SEPTEMBER 6
9:30-11:15 / Session 7: Early detection and treatment
Chairs: Giselle Peters, Instituto Ángel Roffo, Buenos Aires, Argentina and Leandro E. Mainetti, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.
9:30-10:00 Vanesa Gottifredi, Instituto Leloir, Buenos Aires, Argentina.
Targeting the chromosomic instability induced by cancer therapy.
10.00-10:30 Cathrine Park, University of California, San Francisco, USA.
Evolution of breast radiotherapy options for today’s early stage patients.
10:30-10:45 Adriana de Siervi, Oncoliq, CABA-Argentina.
miRNAs for early cancer detection in liquid biopsy.
10:45-11:00 Abstract selected for oral presentation SPARC: a potential biomarker of the transition from in situ to Invasive breast cancer, Marianela Sciacca, Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina.
11:00-11:15 Discussion
11:15-11:45 Coffee Break and free Poster Session
11:45-13:30 / Session 8: Understanding and modeling breast cancer subtypes
Chairs: Paola Rojas, IBYME-CONICET, Buenos Aires, Argentina and María T. Branham, IHEM-CONICET, Mendoza, Argentina
11:45-12:15 Steffi Oestereich, University of Pittsburgh, Pittsburgh, USA.
Invasive lobular breast cancer – what’s different and why is this important?
12:15-12:45 Alana Welm, University of Utah, Salt Lake City, Utah, USA.
Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer
12:45-13:00 Abstract selected for oral presentation: RET receptor integrates tumor cell-adipocyte communication to promote breast cancer. Sabrina A. Vallone, IFIBYNE-UBA-CONICET.
13:00-13:15 Abstract selected for oral presentation: Progesterone promotes triple-negative breast cancer metastasis through RANKL-expressing Treg cells. Tomas Dalotto, IBYME-CONICET.
13:15-13:30 Discussion
13:30-15:00 / Lunch and Poster
15:00-16:00 / Session 9: Improving life quality
Chair: Mario Rossi, Universidad Austral, Pilar, Argentina and
Virginia Novaro, IBYME-CONICET, Buenos Aires
15:15-15:45 Syril Pettit, Health and Environmental Sciences Institute (HESI), Washington DC, USA.
Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients.
15:45-16:00 Discussion
16:00-17:00 / Closing Conference
Chairs: Osvaldo Podhajcer, Instituto Leloir, CONICET, Buenos Aires, Argentina and Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina.
Katherine Hoadley, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
Quantitative Medicine for Breast Cancer Patients.
17:00-17:15 / Discussion and closing remarks by the organizers
17:15-17:30 Coffee break
17:30-19:00 / Round Table 3 (Spanish)
Coordinadores: Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina y Federico Waisberg, Instituto A. Fleming, Buenos Aires, Argentina.
Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama. Situación actual en la región Norte, Centro y Sur del país.
Alejandro Di Sibio coordinador del Programa Nacional de Control de Cáncer de Mama del Instituto Nacional del Cáncer, Buenos Aires, Argentina
Marcela Kober del Instituto Misionero del Cáncer, Posadas, Argentina.
Romina Yapur, Hospital Villa Regina de Río Negro y Centro Oncológico Integral, General Roca, Argentina.